The latest clinical breakthroughs, practice management updates, and national advocacy alerts directly from the American Academy of Ophthalmology.
Achromatopsia treatment wins orphan status
The U.S. FDA has granted orphan drug designation to AGTC’s gene therapy product candidate for the treatment of achromatopsia caused by mutations in the CNGA3 gene.
We extend our deepest gratitude to our Platinum, Gold, and Silver partners. Your generous support fuels our mission to advance medical education, advocate for patient safety, and foster breakthrough innovations across West Virginia.